Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats Human Immunodeficiency Virus (HIV-1) infection. Sold as Retrovir, Zidovudine. Every FDA application for this active ingredient: 6 branded and 14 generic.
As of Nov 16, 2026, FDA lists 20 applications for Zidovudine (sold as Retrovir, Zidovudine), first approved Mar 19, 1987, with 15 new uses approved and 0 published complete response letters.
First approved: Mar 19, 1987
Applications: 20
New uses approved: 15
Complete response letters: 0
Medicare spending, 2025: $164K
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Product
Part
Spending, 2025
Change
Beneficiaries
Zidovudine
Part D
$164K
-3%
358
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
ZIDOVUDINE 300 MG TABLET: $0.464 per unitGeneric · +10% in a year
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA